KIF18A inhibition enhances glioma response to radiotherapy through activation of cGAS–STING signaling
This study demonstrates that inhibiting KIF18A, either genetically or pharmacologically with sovilnesib, sensitizes glioma to radiotherapy by inducing micronuclei-mediated cytosolic DNA accumulation, which activates the cGAS–STING signaling pathway to enhance DNA damage, promote inflammatory responses, and recruit antitumor immunity.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Brain tumors known as gliomas are among the most difficult cancers to treat. Even when doctors remove the visible mass and follow up with radiation therapy to kill remaining cells, the disease often returns. This recurrence happens because some tumor cells survive the radiation, hiding in plain sight and eventually growing back. For decades, scientists have searched for a way to make these stubborn cells more vulnerable to radiation, hoping to turn a temporary setback into a lasting cure. The challenge lies in finding a target that the tumor needs to survive but that healthy brain tissue can do without. One such target has recently come into focus: a protein called KIF18A. This protein acts like a traffic controller inside dividing cells, ensuring that chromosomes—the packages of genetic material—are sorted correctly when a cell splits. When this sorting process goes wrong, the cell can become unstable, a condition that many aggressive tumors rely on to keep growing.
A team of researchers at Xiangya Hospital in China set out to understand how this specific protein influences the success of radiation therapy in glioma patients. They began by looking at vast databases containing genetic information from thousands of patients. Their analysis revealed a clear pattern: patients whose tumors had high levels of KIF18A were much less likely to survive after receiving radiation compared to those with lower levels. This suggested that the protein was helping the tumor resist treatment. To test this idea, the scientists turned to laboratory models, using human glioma cells grown in dishes and in mice. They reduced the amount of KIF18A in these cells, either by using genetic tools to silence the gene or by applying a drug called sovilnesib, which blocks the protein's function. When they exposed these weakened cells to radiation, the results were striking. The cells without KIF18A were far more likely to die than the cells that still had the protein. In mice with brain tumors, the combination of the drug and radiation slowed tumor growth significantly and extended the lives of the animals far more than radiation alone could.
The researchers then dug deeper to understand the mechanism behind this effect. They discovered that when KIF18A is blocked, the cells struggle to divide properly. This struggle causes the chromosomes to get jumbled, leading to the formation of tiny, extra nuclei called micronuclei. These structures are fragile and often burst open, leaking their genetic material into the main body of the cell. The cell recognizes this leaked DNA as a sign of danger, similar to how it would react to a viral infection. This alarm triggers a specific defense pathway known as cGAS–STING. Once activated, this pathway does two critical things. First, it directly damages the tumor cell, pushing it toward death. Second, it sends out chemical signals that recruit the body's immune system, specifically T cells and certain types of white blood cells, to the tumor site. These immune cells then attack the cancer, adding a second layer of defense to the radiation. The study confirmed that if the researchers blocked this immune pathway, the benefits of the drug disappeared, proving that the immune response was essential to the treatment's success.
The team also tested the drug on complex, three-dimensional structures made from actual patient tumor cells, known as organoids, which mimic the real tumor environment better than simple cell cultures. In these models, the combination of the drug and radiation caused more DNA damage and stopped the cells from multiplying. Furthermore, when they looked at the tumors in mice, they found that the treated tumors had fewer signs of cell division and more signs of cell death. Importantly, the drug did not appear to harm the healthy organs of the mice, suggesting it could be safe for use in humans. The study concludes that KIF18A is not just a marker of a dangerous tumor, but a key player in its ability to resist radiation. By inhibiting this protein, doctors could potentially turn a standard radiation treatment into a much more powerful therapy that not only damages the tumor directly but also wakes up the immune system to finish the job. While these findings are currently limited to laboratory and animal models, they offer a promising new direction for treating one of the most challenging forms of brain cancer.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.